These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6081168)

  • 1. [Treatment of lung cancer with Endoxan, with reference to the effect of massive intermittent administration].
    Matsuda M; Nishihara H; Komatsu T; Hattori S; Terasawa T
    Saishin Igaku; 1967 Aug; 22(8):1808-20. PubMed ID: 6081168
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on the administration of massive doses of endoxan in pulmonary neoplasms].
    Górecki R; Brodziak R; Gondorowicz K; Stanek S
    Gruzlica; 1969 Mar; 37(3):251-4. PubMed ID: 4182112
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experience with Endoxan massive treatment].
    Kosaki G; Aoki Y; Kusakabe H; Taniguchi K; Takagi H
    Saishin Igaku; 1966 Nov; 21(11):2527-37. PubMed ID: 5979032
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment with large doses of Endoxan].
    Araujo E; Estevez R; Sanchez Suarez R; Chacon R; Gonzalez G
    Med Monatsschr; 1967 Aug; 21(8):371-3. PubMed ID: 5597100
    [No Abstract]   [Full Text] [Related]  

  • 5. [Shock doses of endoxan in the therapy of malignant lung neoplasms (based on personal observations)].
    Ratajek M
    Wiad Lek; 1970 Jan; 23(1):15-8. PubMed ID: 5412426
    [No Abstract]   [Full Text] [Related]  

  • 6. [Chemotherapy of lung cancer with special reference to combined therapy with mitomycin and endoxan].
    Oka S; Watanabe M; Kato S; Tamagawa S
    Gan No Rinsho; 1966 May; 12(5):271-7. PubMed ID: 6010949
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses.
    Bergsagel DE; Robertson GL; Hasselback R
    Can Med Assoc J; 1968 Mar; 98(11):532-8. PubMed ID: 5643297
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experiences in intermittent massive administration of endoxan for malignant bone tumors, with special reference to osteosarcoma].
    Matsumori S; Watabe E; Kishi H; Kametani H
    Seikei Geka; 1969 May; 20(7):808-13. PubMed ID: 5258756
    [No Abstract]   [Full Text] [Related]  

  • 9. [Incidence and degree of intolerance and toxic effect of cytostatics in the treatment of lung cancer].
    Traczyk K; Zych D; Decker E; Radziukiewicz-Byszewska D; Krychniak W; Marzinek M; Pecyna-Sielewicz J; Ponahajba A; Siekierzyńska A; Słupek A
    Pneumonol Pol; 1980; 48(12):831-40. PubMed ID: 7220354
    [No Abstract]   [Full Text] [Related]  

  • 10. [Case of lung carcinoma treated with massive intravenous administration of Endoxan].
    Frontczak J
    Gruzlica; 1971 May; 39(5):431-2. PubMed ID: 5563839
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers.
    Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK
    Cancer Treat Rep; 1981; 65(5-6):453-8. PubMed ID: 6263477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hematopoiesis during combined treatment of lung cancer patients with cyclophosphan and nitrosomethylurea or CCNU].
    Sokolova II; Trubnikova EN; Trakhtenberg AKh
    Ter Arkh; 1980; 52(9):88-91. PubMed ID: 7434240
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of advanced non-small cell lung cancer.
    Knost JA; Greco FA; Hande KR; Richardson RL; Fer MF; Oldham RK
    Cancer Treat Rep; 1981; 65(11-12):941-5. PubMed ID: 7028255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer.
    Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK; Coles DT
    Cancer Treat Rep; 1981; 65(7-8):715-7. PubMed ID: 6166376
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of a synchronized protocol of cytostatic drugs in the treatment of advanced lung cancer].
    Carrata Thomes A; Gallo E; Valentino V; Onoscuri E; Massola U; Bo M
    Minerva Med; 1981 Jun; 72(25):1669-72. PubMed ID: 7254620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of cisplatin, cyclophosphamide, vincristine, and doxorubicin for the treatment of non-small cell lung cancer.
    Lindgren D; Cadman E; Erichson R; Grann V; Sachs K
    Cancer Treat Rep; 1984 Sep; 68(9):1159-61. PubMed ID: 6090015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of gibberelic acid (GA) alone or together wih cytostatics in treatment of lung cancer.
    Miklussák S; Schwartz E; Dornetzhuber V; Badalík L; Laczko V; Krcová M; Laczková A; Rajecová S; Zemková O
    Neoplasma; 1980; 27(2):203-9. PubMed ID: 7393358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive iv hyperalimentation.
    Jordan WM; Valdivieso M; Frankmann C; Gillespie M; Issell BF; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1981; 65(3-4):197-205. PubMed ID: 6786737
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of non-small cell bronchopulmonary carcinoma with the combination of cyclophosphamide, adriamycin and cisplatin].
    Donnay Candil O; Jiménez Berlana U
    Rev Esp Oncol; 1983; 30(4):603-10. PubMed ID: 6100970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small cell cancer of lung; rapid tumor necrosis leading to serious pulmonary infections after intensive chemotherapy.
    Brandman JR; Ruckdeschel JC; O'Donnell MR; Horton J
    N Y State J Med; 1981 Aug; 81(9):1332-4. PubMed ID: 6267528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.